Knockdown of myosin VI by lentivirus-mediated short hairpin RNA suppresses proliferation of melanoma

Li,Hui; Zhou,Fusheng; Wang,Hongyan; Lin,Da; Chen,Gang; Zuo,Xianbo; Sun,Liangdan; Zhang,Xuejun; Yang,Sen

doi:10.3892/mmr.2015.4261

Knockdown of myosin VI by lentivirus-mediated short hairpin RNA suppresses proliferation of melanoma

Authors:
- Hui Li
- Fusheng Zhou
- Hongyan Wang
- Da Lin
- Gang Chen
- Xianbo Zuo
- Liangdan Sun
- Xuejun Zhang
- Sen Yang
View Affiliations

Affiliations: Department of Dermatology, Institute of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: August 28, 2015 https://doi.org/10.3892/mmr.2015.4261
Pages: 6801-6806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myosin VI has been reported to be associated with the progression of ovarian and prostate cancer. The aim of the present study was to reveal the role of myosin VI in the proliferation of melanoma. Briefly, lentivirus‑mediated short hairpin RNA (shRNA) was designed specifically to silence myosin VI in A375 and A431 cell lines. Expression levels of myosin VI were then analyzed in the two cell lines by quantitative polymerase chain reaction and western blot analyses. Cell viability was assessed using MTT and colony formation assays. In addition, the cell cycle distribution was determined by flow cytometry. The results demonstrated that knockdown of myosin VI significantly suppressed melanoma cell viability and proliferation, and induced cell cycle arrest in G0/G1 phase. To the best of our knowledge, the present study was the first to assess the role of myosin VI in the growth of melanoma. Knowledge of the underlying mechanism of the role myosin VI in skin cancer cells may aid in the development of novel methods of melanoma diagnosis and therapy in the future.

View Figures

View References

1	Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 406:536–540. 2000. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	DeSantis C, Naishadham D and Jemal A: Cancer statistics for African Americans, 2013. CA Cancer J Clin. 63:151–166. 2013. View Article : Google Scholar : PubMed/NCBI
4	Bajetta E, Del Vecchio M, Bernard-Marty C, et al: Metastatic melanoma: Chemotherapy. Semin Oncol. 29:427–445. 2002. View Article : Google Scholar : PubMed/NCBI
5	Overgaard J: The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys. 12:867–872. 1986. View Article : Google Scholar : PubMed/NCBI
6	Shiu MH, Schottenfeld D, Maclean B and Fortner JG: Adverse effect of pregnancy on melanoma: a reappraisal. Cancer. 37:181–187. 1976. View Article : Google Scholar : PubMed/NCBI
7	Dolensek J, Skelin M and Rupnik MS: Calcium dependencies of regulated exocytosis in different endocrine cells. Physiol Res. 60(Suppl 1): 29–38. 2011.
8	Buss F and Kendrick-Jones J: How are the cellular functions of myosin VI regulated within the cell? Biochem Biophys Res Commun. 369:165–175. 2008. View Article : Google Scholar
9	Wells AL, Lin AW, Chen LQ, et al: Myosin VI is an actin-based motor that moves backwards. Nature. 401:505–508. 1999. View Article : Google Scholar : PubMed/NCBI
10	Rock RS, Rice SE, Wells AL, Purcell TJ, Spudich JA and Sweeney HL: Myosin VI is a processive motor with a large step size. Proc Natl Acad Sci USA. 98:13655–13659. 2001. View Article : Google Scholar : PubMed/NCBI
11	Yoshida H, Cheng W, Hung J, et al: Lessons from border cell migration in the drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci USA. 101:8144–8149. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wei S, Dunn TA, Isaacs WB, De Marzo AM and Luo J: GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate. 68:1387–1395. 2008. View Article : Google Scholar : PubMed/NCBI
13	Dunn TA, Chen S, Faith DA, et al: A novel role of myosin VI in human prostate cancer. Am J Pathol. 169:1843–1854. 2006. View Article : Google Scholar : PubMed/NCBI
14	ter Brake O, Konstantinova P, Ceylan M and Berkhout B: Silencing of HIV-1 with RNA interference: A multiple shRNA approach. Mol Ther. 14:883–892. 2006. View Article : Google Scholar : PubMed/NCBI
15	Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL and Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 34:263–264. 2003. View Article : Google Scholar : PubMed/NCBI
16	Samuel CE: Knockdown by RNAi-proceed with caution. Nat Biotechnol. 22:280–282. 2004. View Article : Google Scholar : PubMed/NCBI
17	Pozarowski P and Darzynkiewicz Z: Analysis of cell cycle by flow cytometry. Methods Mol Biol. 281:301–311. 2004.PubMed/NCBI
18	Buss F, Arden SD, Lindsay M, Luzio JP and Kendrick-Jones J: Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-mediated endocytosis. EMBO J. 20:3676–3684. 2001. View Article : Google Scholar : PubMed/NCBI
19	Sahlender DA, Roberts RC, Arden SD, et al: Optineurin links myosin VI to the Golgi complex and is involved in Golgi organi-zation and exocytosis. J Cell Biol. 169:285–295. 2005. View Article : Google Scholar : PubMed/NCBI
20	Morris SM, Arden SD, Roberts RC, et al: Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. Traffic. 3:331–341. 2002. View Article : Google Scholar : PubMed/NCBI
21	Sakakura C, Hagiwara A, Nakanishi M, et al: Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer. 87:1153–1161. 2002. View Article : Google Scholar : PubMed/NCBI
22	Geisbrecht ER and Montell DJ: Myosin VI is required for E-cadherin-mediated border cell migration. Nat Cell Biol. 4:616–620. 2002.PubMed/NCBI
23	Awan A, Lucic MR, Shaw DM, et al: 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun. 290:1030–1036. 2002. View Article : Google Scholar : PubMed/NCBI
24	Sarangarajan R and Boissy RE: Tyrp1 and oculocutaneous albinism type 3. Pigment Cell Res. 14:437–444. 2001. View Article : Google Scholar
25	Morriswood B, Ryzhakov G, Puri C, et al: T6BP and NDP52 are myosin VI binding partners with potential roles in cytokine signalling and cell adhesion. J Cell Sci. 120:2574–2585. 2007. View Article : Google Scholar : PubMed/NCBI
26	Mok SC, Chan WY, Wong KK, et al: DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene. 16:2381–2387. 1998. View Article : Google Scholar : PubMed/NCBI
27	Jung EJ, Liu G, Zhou WJ and Chen XB: Myosin VI is a mediator of the p53-dependent cell survival pathway. Mol Cell Biol. 26:2175–2186. 2006. View Article : Google Scholar : PubMed/NCBI